¿ Por qué nunca se ha demostrado que el cribado del cáncer salve vidas? V Prasad, J Lenzer, DHN Fuente | | |
1349 EDITOR’S NOTE JC Ballantyne, MD Sullivan, A Kolodny, RR Khanna, RG Victor, ... ARCH INTERN MED 172 (17), 2012 | | 2012 |
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature G Nishikawa, J Luo, V Prasad European Journal of Cancer 101, 143-151, 2018 | 20 | 2018 |
A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals D Herrera-Perez, A Haslam, T Crain, J Gill, C Livingston, V Kaestner, ... Elife 8, e45183, 2019 | 115 | 2019 |
A conversation with Vinay Prasad, MD: To'first, do no harm,'you must start with good evidence V Prasad | | 2016 |
A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices V Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ... Mayo Clinic Proceedings, 2013 | 438 | 2013 |
A further strategy to combat the high price of anticancer drugs V Prasad, K De Jesús, S Mailankody Nature Reviews Clinical Oncology 14 (10), 629, 2017 | 4 | 2017 |
À la carte medicine V Prasad Canadian Medical Association Journal 182 (18), 2011-2012, 2010 | | 2010 |
A medical burden of proof: Towards a new ethic V Prasad, A Cifu Biosocieties, doi: 10.1057/biosoc.2011., 2012 | 23 | 2012 |
A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment J Gill, V Prasad Research and Practice in Thrombosis and Haemostasis 4 (1), 19, 2020 | 1 | 2020 |
A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer K Powell, T Olivier, V Prasad Trials 23 (1), 1044, 2022 | 1 | 2022 |
A pooled analysis of published, basket trials in cancer medicine A Hazim, V Prasad European Journal of Cancer 101, 244-250, 2018 | 21 | 2018 |
A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers V Prasad, A Haslam, J Tuia Journal of Cancer Policy 31, 100319, 2022 | 1 | 2022 |
A reality check of the accelerated approval of immune-checkpoint inhibitors J Gill, V Prasad Nature Reviews Clinical Oncology 16 (11), 656-658, 2019 | 35 | 2019 |
A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials A Maniar, V Prasad, A Haslam | | 2021 |
A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target A Haslam, T Olivier, J Tuia, V Prasad European Journal of Cancer 178, 227-233, 2023 | 3 | 2023 |
A Systematic Review of Evidence Behind the CDC Guidelines for Indoor Lightning Safety V Prasad, EMD Brown, A Haslam medRxiv, 2023.10. 05.23296621, 2023 | | 2023 |
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda J Luo, G Nishikawa, V Prasad Journal of Cancer Research and Clinical Oncology 145, 2303-2311, 2019 | 11 | 2019 |
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology A Haslam, SP Hey, J Gill, V Prasad European Journal of Cancer 106, 196-211, 2019 | 171 | 2019 |
A timeline of immune checkpoint inhibitor approvals in small cell lung cancer J Gill, JP Cetnar, V Prasad Trends in Cancer 6 (9), 736-738, 2020 | 6 | 2020 |